BDBM328869 (S)-4-(N-((4-((3-chloro-4- fluorophenyl)sulfonyl)-6-((((1,1,1- trifluoro-2-methylpropan-2- yl)oxy)carbonyl)amino)-3,4-dihydro- 2H-benzo[b][1,4]oxazin-2- yl)methyl)sulfamoyl)-3,5- dimethylisoxazole::US9663502, 38AC

SMILES Cc1noc(C)c1S(=O)(=O)NC[C@H]1CN(c2cc(NC(=O)OC(C)(C)C(F)(F)F)ccc2O1)S(=O)(=O)c1ccc(F)c(Cl)c1

InChI Key InChIKey=AZERVTOBINCKRP-UHFFFAOYSA-N

Data  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 328869   

TargetNuclear receptor ROR-gamma(Human)
Lycera

US Patent
LigandPNGBDBM328869((S)-4-(N-((4-((3-chloro-4- fluorophenyl)sulfonyl)-...)
Affinity DataIC50: 20.4nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
US Patent